Target intelligence / Profile preview

Lethal factor (LF)

Target
LF
Molecular classification
Enzyme, Metalloprotease, Bacterial toxin component
01

Overview

Lethal factor (LF) is a secreted bacterial enzyme that forms one of the three components of anthrax toxin, produced by Bacillus anthracis[4][8]. LF is a zinc-dependent metalloprotease with a molecular mass of about 90 kDa, structurally composed of four domains: one mediates binding to protective antigen (PA), which is required for host cell entry, while the other domains create a substrate-binding groove and house the catalytic center[1][2]. Once introduced into host cytosol by PA, LF cleaves and inactivates most MAPKK (MEK) family proteins by cutting within their N-terminal proline-rich regions, leading to disrupted intracellular signaling, immune cell death (especially macrophages), and a general dysregulation of host immune responses[1][2][4][8]. LF, in combination with PA, forms "lethal toxin" (LeTx), and is essential for the pathogenesis and lethality of anthrax infections. LF-specific inhibitors have been developed as research tools, but there are no licensed drugs specifically targeting LF in clinical scenarios[10].

Other names
LFAnthrax lethal factorBacillus anthracis lethal factor
02

Mechanism of action

Inhibition of LF enzymatic activity (metalloprotease inhibition)[10]. Blockade of MAPKK cleavage. Preventing LF entry into the host cell cytosol (by interfering with the assembly or translocation with protective antigen)[3][8]

03

Biological functions

Proteolytic cleavage of mitogen-activated protein kinase kinases (MAPKKs)Inhibition of intracellular signaling pathwaysInduction of cell death (particularly macrophage death)Immune system suppressionPromotion of inflammasome activation and pyroptosis in specific rodents
04

Disease associations

Infection (critical virulence factor in anthrax caused by Bacillus anthracis)
05

Safety considerations

Potent cytotoxicity when delivered as part of anthrax toxin complexRisk of rapid cell and organ death if LF is not neutralized in acute anthraxNo notable therapeutic safety concerns since direct clinical use is not approved; inhibitors under investigation must avoid off-target metalloprotease effects[10]
06

Interacting drugs

Anthrax Lethal Factor Protease Inhibitor III (also known as BI-11B3, BDBM8443)[10]

2 more in the full profile.

07

Biomarkers

None in clinical use specifically for LF; anthrax diagnosis involves detection of Bacillus anthracis DNA, toxins, or immune response rather than LF as a stand-alone biomarker

Beyond the preview

Go deeper on Lethal factor (LF).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lethal factor (LF).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call